New prostate cancer test could help avoid unnecessary biopsies

Credit: Unsplash+

Alberta introduces an innovative step towards accurate diagnosis and potentially sparing men from unnecessary prostate biopsies with the advent of the ClarityDX Prostate test.

Traditionally, an elevated level of Prostate-Specific Antigen (PSA) triggers a biopsy to confirm prostate cancer. However, PSA levels can be influenced by various non-cancerous factors, hence sometimes leading to unnecessary biopsies.

More Than Just a Blood Test

The ClarityDX Prostate test takes the conventional testing a step further by providing additional insightful information.

The methodology, detailed in Cancer Medicine, combines data regarding prostate cancer biomarkers present in the blood with clinical data, applying machine learning to formulate a risk score indicative of clinically significant prostate cancer.

Efficacy and Accuracy in Real-World Scenarios

A study scrutinizing the outcomes for 415 men from Alberta, who underwent biopsies following elevated PSA levels between 2014 and 2017, yielded impressive results.

The ClarityDX Prostate test successfully predicted which patients had high-grade, clinically significant prostate cancer that necessitated treatment with an astonishing 95% accuracy.

Additionally, the test could have precluded around 35% of the patients from undergoing recommended biopsies as they did not harbor clinically significant cancer.

Furthermore, according to an unpublished clinical validation study involving 3,448 men from Alberta and the U.S., the ClarityDX Prostate test is cited as being threefold more accurate than the conventional PSA test at identifying clinically significant prostate cancer.

The study propounds that utilizing this test could abate up to 37% of unwarranted biopsies and markedly diminish the number of unnecessary treatments for prostate cancer.

The Team and Technology Behind the Innovation

Developed at the University of Alberta and patented by Nanostics Inc., the ClarityDX Prostate test is not just a breakthrough product but a harbinger of the technology’s potential.

John Lewis, the Bird Dogs Chair in Translational Oncology at the University of Alberta and CEO of Nanostics Inc., asserts that the ClarityDX Prostate test will mitigate the instances of unneeded invasive prostate biopsies, which are not only discomforting but also pose some risks to the patients.

Prospects Beyond Prostate Cancer

Encouraged by the results, the Lewis team is delving into utilizing the same technological foundation to conjure a predictive test for bladder cancer.

Moreover, the team envisions the applicability of this technology in devising diagnostic tools for a myriad of other ailments, which include cardiac diseases, infectious diseases, and neurodegenerative diseases.

In conclusion, the introduction of the ClarityDX Prostate test stands out as a testament to how the amalgamation of technology, research, and clinical data can sculpt the future of diagnostic procedures, not only refining accuracy but also enhancing patient care and experience by potentially evading unnecessary procedures.

As further studies and real-world applications unfold, the health care community and patients alike will keenly observe the tangible impacts and further potentials of this pioneering technology.

If you care about prostate cancer, please read studies about 5 types of bacteria linked to aggressive prostate cancer, and new strategy to treat advanced prostate cancer.

For more information about prostate cancer, please see recent studies about new way to lower risk of prostate cancer spread, and results showing three-drug combo boosts survival in metastatic prostate cancer.

The research findings can be found in Cancer Medicine.

Follow us on Twitter for more articles about this topic.

Copyright © 2023 Knowridge Science Report. All rights reserved.